What the FDA Is Warning About
Few drug classes have transformed medicine as dramatically as GLP-1 receptor agonists, the family that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Initially approved for diabetes, they are now prescribed widely for weight loss and metabolic syndrome, driving unprecedented demand. But that same popularity has fueled an underground market of unapproved or compounded versions, often sold online or through aesthetic or “wellness” clinics.
In late 2024, the U.S. Food and Drug Administration (FDA) issued an expanded safety alert warning against the purchase or use of any “compounded,” “research-only,” or “generic” semaglutide or tirzepatide promoted for weight loss. The agency emphasized that these products are not FDA-approved, have not been evaluated for safety or efficacy, and in many cases contain the wrong chemical form of the active ingredient – most commonly semaglutide sodium or semaglutide acetate. These salts differ structurally from the approved molecule and have never undergone human testing. The warning followed dozens of adverse event reports, including hospitalizations linked to overdosing, contamination, and inconsistent dosing. Some patients were found to have injected compounded mixtures many times stronger or weaker than the intended dose. In several cases, laboratory testing revealed bacterial contamination or undeclared additives.
Under federal law, pharmacies may only compound a copy of an FDA-approved drug during an official shortage and only with ingredients chemically identical to the approved product. The FDA clarified that many of the “semaglutide” products marketed online or through social-media influencers violate this rule. Furthermore, the sale of “research-only” or “not for human use” formulations to consumers constitutes illegal distribution of unapproved drugs.
The agency’s statement is unusually forceful: it specifically calls out both compounders and telehealth prescribers, reminding clinicians that prescribing or dispensing unapproved GLP-1 formulations may trigger civil or criminal penalties. Enforcement actions are already underway, with several compounding pharmacies and digital clinics receiving warning letters or referrals to the Department of Justice. The FDA’s message is clear. Demand pressure does not justify circumventing the drug approval process or patient safety standards.
Why Now
The timing of the FDA’s intensified warning—October 2024—reflects a perfect storm. Ongoing supply constraints for Wegovy and Mounjaro left patients desperate, while social-media marketing amplified consumer demand. Thousands turned to online “research-chemical” vendors promising cheaper semaglutide “for personal research use,” many of them operating outside state pharmacy oversight.
Simultaneously, insurers and pharmacy benefit managers (PBMs) began tightening prior authorization for legitimate GLP-1 therapies, unintentionally pushing some consumers toward unapproved alternatives. Poison-control centers reported a spike in calls related to compounded or mislabeled semaglutide injections. In response, the FDA launched a coordinated enforcement effort with the Federal Trade Commission (FTC) and state pharmacy boards, warning both providers and consumers that these products pose real risks of toxicity, infection, and dosage miscalculation.
In short, the agency’s renewed alert comes at a moment when market scarcity, digital marketing, and cost barriers have converged to create a black-market ecosystem around GLP-1 drugs, forcing regulators to act decisively before patient harm becomes systemic.
How Compounded GLP-1s Circumvent Regulation
The market for unapproved GLP-1 drugs has flourished by exploiting regulatory gray zones in U.S. pharmacy law. Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are permitted to prepare custom medications for individual patients, but only when the compounded version is identical to an FDA-approved product and when that product is in verified shortage. These exceptions are meant for rare or urgent cases, such as sterile injectables that hospitals can’t obtain through standard supply chains.
However, the rapid rise in consumer demand for semaglutide and tirzepatide created fertile ground for misuse of these rules. Many operators began producing or importing semaglutide sodium or semaglutide acetate, chemically distinct salts that have never been approved for human use. These compounds are easier to source in bulk from chemical suppliers and can be sold at a fraction of the cost of Wegovy or Ozempic. Once purchased, they are reconstituted and sold through wellness clinics, med-spas, or telehealth storefronts, often accompanied by vague disclaimers such as “for research purposes only.” In practice, these products are marketed directly to consumers for injection, bypassing FDA review, labeling requirements, and sterility standards.
The FDA has emphasized that compounding from semaglutide salts is illegal because these substances differ from the base molecule used in Novo Nordisk’s approved drugs. Legitimate 503A and 503B compounding facilities must source their active ingredients from FDA-registered suppliers using the same active pharmaceutical ingredient (API) as the approved drug. Yet hundreds of small pharmacies and online vendors skirt this rule by claiming their ingredients are “chemically equivalent” or by avoiding patient-specific prescriptions altogether. Some purchase powdered semaglutide from overseas brokers who operate outside U.S. quality-control systems, leaving the final product vulnerable to contamination or dosing variability. Federal and state regulators have begun to close these loopholes. In 2024, the FDA issued multiple warning letters to compounders and raw-ingredient distributors, and several states, including Florida, Texas, and California, initiated board of pharmacy investigations into clinics advertising compounded GLP-1 injections for weight loss. Seized samples revealed wide potency deviations, sometimes exceeding 400% of the labeled dose.
Public-health consequences are already visible. Poison control centers report increasing calls involving compounded semaglutide overdoses, usually from patients attempting to self-titrate with research-grade vials. Hospitals have treated cases of nausea, dehydration, and acute kidney injury from misformulated or contaminated products. Even compounding pharmacies acting in good faith risk enforcement if they continue preparing these injectables without an FDA-declared shortage.
The result is a fractured landscape: legitimate pharmacists squeezed between patient demand and federal warnings, and unscrupulous vendors exploiting ambiguity for profit. The FDA’s stance is now unambiguous. Any GLP-1 product not made from the FDA-approved active ingredient and labeled for human use is unlawful, regardless of how it is marketed or sourced.
The Insurance and PBM Perspective
As the FDA intensifies its crackdown on unapproved GLP-1 formulations, insurers and pharmacy benefit managers (PBMs) are scrambling to manage the collateral effects: rising member demand, high drug costs, and growing patient confusion about what is legitimate. The explosion of compounded and “research-only” semaglutide and tirzepatide has forced payers to draw hard lines in their formularies while balancing access for patients who genuinely need treatment for diabetes or cardiovascular disease.
Most major health plans now explicitly exclude compounded GLP-1 formulations from coverage. Their rationale is straightforward: unless a product is listed as an FDA-approved drug or compounded using the same active ingredient during a verified shortage, it is not reimbursable under federal or state insurance standards. As of early 2025, Wegovy, Ozempic, Mounjaro, and Zepbound are the only semaglutide and tirzepatide formulations that meet this definition. When members submit claims for unapproved compounded versions, often under vague names like “semaglutide 5 mg/mL”, the system automatically denies payment, flagging them as non-formulary or unverified NDC codes.
From the payer’s standpoint, the issue is not just legality but liability. If an insurer reimburses an unapproved product and a patient experiences harm, the plan could face litigation or federal scrutiny for facilitating the distribution of an unlicensed drug. PBMs, too, have legal exposure if they process claims for substances later deemed counterfeit or unsafe. To mitigate risk, many plans have implemented data-matching protocols that cross-reference every GLP-1 claim against FDA’s National Drug Code (NDC) directory and Drug Shortages database. Anything that falls outside these registries is blocked automatically. Behind the scenes, PBMs have launched internal task forces to track GLP-1 activity in real time. Using data from wholesalers, manufacturer supply chains, and the FDA, they identify potential “gray-market inflows” – sudden claim spikes in specific geographic areas or from certain telehealth networks. Plans then alert state regulators or pharmacies if they suspect illegal distribution. Several PBMs have also suspended contracts with online telemedicine vendors that advertise compounded semaglutide or tirzepatide, citing compliance concerns.
Patient education has become a top priority. Health insurers are sending mass communications warning members not to purchase GLP-1 drugs from unverified online sources or med-spas. Many now include specific language in their Explanation of Benefits statements: “Your plan does not cover compounded or unapproved versions of GLP-1 medications. Using these products may pose serious safety risks.” Customer-service teams are being trained to distinguish between legitimate compounded drugs (rare and strictly regulated) and illicit “research-only” formulations marketed through social media.
At the same time, PBMs are under pressure to ensure legitimate access amid shortages and rising costs. To maintain member trust, some have temporarily eased prior authorization (PA) requirements for FDA-approved GLP-1s used in diabetes or cardiovascular indications. Others are adding tiered cost-sharing options or broader coverage for alternative agents like liraglutide (Victoza) or dulaglutide (Trulicity) to help patients avoid unsafe substitutes. Still, insurers acknowledge that rigid denials can inadvertently push patients toward the very black-market products regulators warn against. Several plans are therefore experimenting with patient-safety outreach programs that combine coverage counseling with referrals to legitimate telehealth prescribers and manufacturer savings programs. The strategy reflects a broader ethical tension: while payers must enforce FDA compliance, they also recognize that cost and access barriers often drive patients to riskier, illegal options.
For the insurance industry, the unapproved GLP-1 crisis is a cautionary tale. It highlights the fragile boundary between coverage exclusion and patient desperation, and it underscores why regulatory clarity and adequate drug supply are as essential to safety as the compounds themselves.
Legal, Ethical, and Market Fallout
The FDA’s intensified campaign against unapproved GLP-1 compounds has triggered a wave of legal, ethical, and market repercussions reverberating across the healthcare industry. Enforcement actions that began as warning letters have escalated into criminal investigations, civil lawsuits, and disciplinary proceedings against prescribers and pharmacies that ignored federal guidance. The Department of Justice, working with the FDA’s Office of Criminal Investigations, is now targeting entities that imported or sold semaglutide sodium or tirzepatide acetate under the guise of “research use.”
Clinicians are divided; some defend limited compounding as a form of harm reduction during genuine shortages, arguing that patients denied insurance coverage or access to brand-name drugs should not be left untreated. Others see this as indefensible: prescribing untested, illegally compounded hormones endangers patients and undermines the legitimacy of medical practice. Several state medical and pharmacy boards have begun suspending licenses of providers found promoting “research-grade” GLP-1s on social media, emphasizing that patient desperation cannot override drug safety laws.
The fallout extends to the marketplace. Consumers who experienced adverse events from compounded semaglutide are filing lawsuits against weight-loss clinics and telehealth startups, alleging negligence and product misrepresentation. Major pharmacy chains have issued internal compliance bulletins banning the dispensing of any semaglutide not sourced from FDA-approved distributors.
Manufacturers, including Novo Nordisk and Eli Lilly, have publicly supported the FDA’s stance and initiated their own legal actions against compounders infringing on intellectual property or endangering patients.
Ethically, the crisis exposes the darker side of medical commercialization — where viral marketing, telehealth convenience, and patient demand outpaced regulatory oversight. The coming year will likely see tighter compounding enforcement, expanded interstate investigations, and new federal policy proposals clarifying when compounding is permissible during shortages. For now, the FDA’s message stands as precedent: the age of “research-use” GLP-1s masquerading as medicine is over.
References
U.S. Food and Drug Administration. (2024, October 24). FDA’s concerns with unapproved GLP-1 drugs used for weight loss. U.S. Department of Health & Human Services.
Reuters. (